Sumitomo Mitsui Trust Group Inc. Has $100.06 Million Stock Holdings in Becton, Dickinson and Company $BDX

Sumitomo Mitsui Trust Group Inc. lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.4% in the first quarter, Holdings Channel reports. The firm owned 636,370 shares of the medical instruments supplier’s stock after selling 29,126 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Becton, Dickinson and Company were worth $100,056,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Imprint Wealth LLC bought a new position in shares of Becton, Dickinson and Company during the third quarter worth $25,000. Steph & Co. raised its stake in Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 65 shares during the period. SHP Wealth Management bought a new position in Becton, Dickinson and Company during the fourth quarter worth about $26,000. Prosperity Bancshares Inc bought a new position in Becton, Dickinson and Company during the fourth quarter worth about $29,000. Finally, WPG Advisers LLC grew its stake in Becton, Dickinson and Company by 64.2% in the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 61 shares during the period. Institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on BDX. Piper Sandler dropped their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a research note on Monday. Weiss Ratings cut shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Finally, TD Cowen lowered their price objective on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a research report on Monday, May 4th. Seven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $180.29.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. This trade represents a 7.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 5,188 shares of company stock worth $765,120 over the last quarter. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.9%

Shares of NYSE:BDX traded up $1.31 during mid-day trading on Friday, reaching $152.16. 1,048,159 shares of the stock were exchanged, compared to its average volume of 2,698,424. The stock’s 50 day simple moving average is $148.25 and its 200-day simple moving average is $167.81. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35. The company has a market cap of $41.93 billion, a P/E ratio of 38.52, a P/E/G ratio of 10.67 and a beta of 0.21. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, equities research analysts predict that Becton, Dickinson and Company will post 12.62 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th were given a $1.05 dividend. The ex-dividend date of this dividend was Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.